be established by these measures. As the addition of CSF-mobilized peripheral blood progenitor cells (PBPC) to autologous bone marrow (BM) grafts markedly improves hematopoietic recovery?' infusion of donor-derived PBPC may also help to overcome insufficient hematopoiesis after allogeneic BMT: here we report the first case of successful transplantation of granulocyte CSF (G-CSF)-mobilized allogeneic PBPC after the repeated failure of CSF-promoted BM grafts.
A 47-year-old cytomegalovirus (CMV)-positive female with AML in first CR received a BM graft (cell dose 1.56 X 108/kg) from her HLA-matched blood group mismatched sister (donor A, recipient B) after standard conditioning with 12 Gy TBI and 120 mg/kg cyclophosphamide. Prophylaxis for graft-versus-host disease (GVHD) consisted of cyclosporine A and short course methotrexate. Although restriction fragment length polymorphism (RFLP) typing of marrow aspirates showed DNA of donor origin, there was no clinical evidence of engraftment (white blood cell [WBC] count i O.l/nL, BM cellularity < 5%). On day +32, a second BM graft from the same donor (cell dose 2.46 X 108/kg) was given after preparation with anti-thymocyte globulin (4 X 0.5 mL/kg Lymphoglobuline; Pasteur Merieux, Lyon, France). To promote marrow recovery, granulocyte-macrophage CSF (GM-CSF) (250 pglm'; Sandoz, Nuremberg, Germany) was administered from day 0 to + 18 and interleukin-3 (IL-3, 10 pg/ kg; Sandoz) from day +I9 to +35 after the second BMT. Peripheral blood leukocytes appeared on day +6, and the WBC count increased rapidly to 15/nL, although the BM cellularity remained poor (4%). The patient developed mild acute GVHD, which was limited to the skin (grade I). When IL-3 was stopped, a rapid decrease of the WBC count to <0.5/nL occurred, which proved irreversible despite a further course of IL-3. PBPC were mobilized from the marrow donor by daily subcutaneous injections of G-CSF (6 pg/kg; Amgen, Munich, Germany), which resulted in a leukocytosis of 38 to 50 cells/nL. On days 7, 8, and 9 after initiation of G-CSF, three leukapheresis procedures yielded a total number of 13.52 X 108/kg mononuclear cells. The leukapheresis product contained 4.04 X 108/kg CD3+ cells and 8.16 X IO6/ kg CD34+ cells and was infused without further processing. The donor tolerated the mobilization and cell separation procedures well.
Because RFLP typing of peripheral blood and bone marrow had demonstrated only donor bands (see Fig 2) , PBPC transplantation was performed without further immunosuppressive therapy on days 9 1 to 93 after first BMT. G-CSF (10 pg/kg) was administered for 26 days after PBPC infusion. The WBC count exceeded 1 .O/nL on day + 1 1, and BM cellularity was 10% on day + 14. Moderate acute GVHD (grade 11, skin) started on day + 18. Intensification of immunosuppressive treatment with high-dose steroids ( I6 mg/kg) and anti-IL-2 receptor monoclonal antibody (Biotest, Dreieich, Germany) was followed by a decrease of the WBC count to 1.5/nL; CMV-PCR became positive again, suggesting a reactivation of CMV infection (Fig 1) . After cessation ofthe monoclonal antibody, reduction of the prednisolone dose (1.5 mg/kg with slow tapering), antiviral treatment (ganciclovir day +37 to +49), and renewed G-CSF administration (day +39 to +58), a stable WBC count (3 to 4/nL) was achieved. On day +66, BM histology showed a cellularity of 15% with trilineage engraftment. RFLP typing demonstrated DNA of donor origin only (Fig 2) . Subsequently, the BM function improved slowly; the patient Analysis before PBPC infusion (from left to right): 1, BM donor; 2, peripheral blood day + 91 ; 3, BM day + 60; 4, peripheral blood day + 60; 5, peripheral blood day + 50 after first BMT: 6, BM recipient pre-BMT; 7 , peripheral blood recipient pre-BMT. (B) Analysis after PBPC infusion (from left to right): 1, BM donor; 2, peripheral blood day + 56; 3, BM day + 56; 4, peripheral blood day + 28; 5, BM day + 14 after PBPC infusion; 6, BM recipient pre-BMT. Only donor DNA is detectable after PBPC transplantation. now (day +260) has a WBC count of 7.5/nL without growth factor support and is independent of platelet and red blood cell (RBC) sup port. BM histology shows trilineage engraftment (cellularity I"%) without evidence of leukemia. As blood group serology and RFLP typing revealed, hematopoiesis is exclusively donor derived. CMV DNA is absent from peripheral blood leukocytes. A generalized mild maculo-squamous exanthema is consistent with chronic GVHD, as confirmed by skin biopsy.
Peripheral blood progenitor cells, mobilized by CSF and/or cytotoxic chemotherapy, can be harvested for the purpose of stem cell rescue after myeloablative highdose chemotherapy. The resulting preparations usually contain high numbers of progenitors when compared with conventional BM graRs.2 Infusion of growth factormobilized PBPC markedly accelerates blood cell recovery after autologous BMT,24 indicating that PBPC can add substantial hematopoietic potential to marrow grafts. The course of events in this patient (see Fig I ) demonstrates that otherwise refractory graft failure after allogeneic BMT can be overcome by infusion of G-CSF-mobilized PBPC, even in a situation where the chance of successful engraftment of BM cells would appear very low. Severe GVHD did not develop although the extremely high number of T cells infused with the PBPC caused considerable concern in that direction. In particular, the intensity of acute GVHD was not worse than the GVHD episode after the second marrow graft. suggesting that the quality (ie, specificity) rather than the quantity ofdonor T cells seems to be the more important determinant influencing GVHD intensity.
On the other hand, the T cells contained in the PBPC inoculum may have facilitated engraft~nent.~ Since recurrent CMV viremia was demonstrated in our patient, CMV infection may have contributed to the poor function of the BM graft! Thus, it cannot be ruled out that hematopoietic recovery after PBPC infusion was influenced by control of CMV infection. However, the striking increase of the leukocyte count at a time typically expected after PBPC infusion, and the fact that graft function was not grossly affected during subsequent renewed CMV reactivation argue against this interpretation.
Taken together, this case indicates that allogeneic PBPC transplantation is feasible without causing detrimental GVHD and may be useful. at least in situations in which a BM graft fails or is not available. 
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